The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Splenomegaly


Psychiatry related information on Splenomegaly


High impact information on Splenomegaly


Chemical compound and disease context of Splenomegaly

  • However, delta9-THC administered daily for 10 days significantly inhibited Friend leukemia virus-induced splenomegaly by 71% at 200 mg/kg as compared to 90.2% for actinomycin D [13].
  • The immunostimulatory effect of adriamycin and C. parvum administered as a single agent or in combination was associated with significant splenomegaly [14].
  • Only the active fragmented, pyridine residue and unfractionated preparations caused splenomegaly and prevented the secondary in vitro generation of CTL [15].
  • Serum bilirubin concentration, histological stage on liver biopsy, age, and the presence of splenomegaly were independent predictors of a high risk of dying [16].
  • 188 schoolchildren aged 10-15 living in a malaria endemic area along the Thai-Burmese border were matched for age, splenomegaly, and weight and were then randomly assigned to receive either doxycycline (adult equivalent of 100 mg daily) or chloroquine (adult equivalent of 300 mg base weekly) [17].

Biological context of Splenomegaly


Anatomical context of Splenomegaly


Gene context of Splenomegaly


Analytical, diagnostic and therapeutic context of Splenomegaly



  1. Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. You-Ten, K.E., Muise, E.S., Itié, A., Michaliszyn, E., Wagner, J., Jothy, S., Lapp, W.S., Tremblay, M.L. J. Exp. Med. (1997) [Pubmed]
  2. Complement C4 inhibits systemic autoimmunity through a mechanism independent of complement receptors CR1 and CR2. Chen, Z., Koralov, S.B., Kelsoe, G. J. Exp. Med. (2000) [Pubmed]
  3. Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice. Clouthier, D.E., Comerford, S.A., Hammer, R.E. J. Clin. Invest. (1997) [Pubmed]
  4. Portal hypertension in vinyl chloride monomer workers. A hemodynamic study. Blendis, L.M., Smith, P.M., Lawrie, B.W., Stephens, M.R., Evans, W.D. Gastroenterology (1978) [Pubmed]
  5. Chylomicronemia induced by cimetidine. Iverius, P.H., Brunzell, J.D. Gastroenterology (1985) [Pubmed]
  6. Nodular regenerative hyperplasia of the liver: the importance of combined macroscopic and microscopic findings. Forbes, G.M., Shilkin, K.B., Reed, W.D. Med. J. Aust. (1991) [Pubmed]
  7. Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: a direct comparison with systemic IL-12 protein therapy. Rakhmilevich, A.L., Timmins, J.G., Janssen, K., Pohlmann, E.L., Sheehy, M.J., Yang, N.S. J. Immunother. (1999) [Pubmed]
  8. Gain- and loss-of-function Lyn mutant mice define a critical inhibitory role for Lyn in the myeloid lineage. Harder, K.W., Parsons, L.M., Armes, J., Evans, N., Kountouri, N., Clark, R., Quilici, C., Grail, D., Hodgson, G.S., Dunn, A.R., Hibbs, M.L. Immunity (2001) [Pubmed]
  9. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Moriggl, R., Topham, D.J., Teglund, S., Sexl, V., McKay, C., Wang, D., Hoffmeyer, A., van Deursen, J., Sangster, M.Y., Bunting, K.D., Grosveld, G.C., Ihle, J.N. Immunity (1999) [Pubmed]
  10. Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. Velazquez, L., Cheng, A.M., Fleming, H.E., Furlonger, C., Vesely, S., Bernstein, A., Paige, C.J., Pawson, T. J. Exp. Med. (2002) [Pubmed]
  11. Idiotypes expressed early in experimental Schistosoma mansoni infections predict clinical outcomes of chronic disease. Montesano, M.A., Colley, D.G., Willard, M.T., Freeman, G.L., Secor, W.E. J. Exp. Med. (2002) [Pubmed]
  12. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. Hattori, K., Dias, S., Heissig, B., Hackett, N.R., Lyden, D., Tateno, M., Hicklin, D.J., Zhu, Z., Witte, L., Crystal, R.G., Moore, M.A., Rafii, S. J. Exp. Med. (2001) [Pubmed]
  13. Antineoplastic activity of cannabinoids. Munson, A.E., Harris, L.S., Friedman, M.A., Dewey, W.L., Carchman, R.A. J. Natl. Cancer Inst. (1975) [Pubmed]
  14. Effect of adriamycin and Corynebacterium parvum in tumor-bearing mice: modulation of response to sheep red blood cells. Dimitrov, N.V., Denny, T.N., Weisman, M.F., Cameron, D.G. J. Natl. Cancer Inst. (1979) [Pubmed]
  15. Effects of different fractions of Corynebacterium parvum on the cytotoxic T-cell response to alloantigens in mice. Lichtenstein, A., Tuttle, R., Cantrell, J., Zighelboim, J. J. Natl. Cancer Inst. (1982) [Pubmed]
  16. Primary sclerosing cholangitis: refinement and validation of survival models. Dickson, E.R., Murtaugh, P.A., Wiesner, R.H., Grambsch, P.M., Fleming, T.R., Ludwig, J., LaRusso, N.F., Malinchoc, M., Chapman, R.W., Kaplan, M.M. Gastroenterology (1992) [Pubmed]
  17. Doxycycline prophylaxis for falciparum malaria. Pang, L.W., Limsomwong, N., Boudreau, E.F., Singharaj, P. Lancet (1987) [Pubmed]
  18. Friend spleen focus-forming virus production in vitro by a nonerythroid cell line. Clarke, B.J., Axelrad, A.A., Housman, D. J. Natl. Cancer Inst. (1976) [Pubmed]
  19. Reduced PU.1 expression causes myeloid progenitor expansion and increased leukemia penetrance in mice expressing PML-RARalpha. Walter, M.J., Park, J.S., Ries, R.E., Lau, S.K., McLellan, M., Jaeger, S., Wilson, R.K., Mardis, E.R., Ley, T.J. Proc. Natl. Acad. Sci. U.S.A. (2005) [Pubmed]
  20. Large, chronic doses of erythropoietin cause thrombocytopenia in mice. McDonald, T.P., Clift, R.E., Cottrell, M.B. Blood (1992) [Pubmed]
  21. High levels of osteopontin associated with polymorphisms in its gene are a risk factor for development of autoimmunity/lymphoproliferation. Chiocchetti, A., Indelicato, M., Bensi, T., Mesturini, R., Giordano, M., Sametti, S., Castelli, L., Bottarel, F., Mazzarino, M.C., Garbarini, L., Giacopelli, F., Valesini, G., Santoro, C., Dianzani, I., Ramenghi, U., Dianzani, U. Blood (2004) [Pubmed]
  22. Perturbed myelo/erythropoiesis in Lyn-deficient mice is similar to that in mice lacking the inhibitory phosphatases SHP-1 and SHIP-1. Harder, K.W., Quilici, C., Naik, E., Inglese, M., Kountouri, N., Turner, A., Zlatic, K., Tarlinton, D.M., Hibbs, M.L. Blood (2004) [Pubmed]
  23. Rheumatoid arthritis associated with expanded populations of granular lymphocytes. Barton, J.C., Prasthofer, E.F., Egan, M.L., Heck, L.W., Koopman, W.J., Grossi, C.E. Ann. Intern. Med. (1986) [Pubmed]
  24. v-abl causes hematopoietic disease distinct from that caused by bcr-abl. Scott, M.L., Van Etten, R.A., Daley, G.Q., Baltimore, D. Proc. Natl. Acad. Sci. U.S.A. (1991) [Pubmed]
  25. Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells. Imren, S., Payen, E., Westerman, K.A., Pawliuk, R., Fabry, M.E., Eaves, C.J., Cavilla, B., Wadsworth, L.D., Beuzard, Y., Bouhassira, E.E., Russell, R., London, I.M., Nagel, R.L., Leboulch, P., Humphries, R.K. Proc. Natl. Acad. Sci. U.S.A. (2002) [Pubmed]
  26. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Peters, D.G., Hoover, R.R., Gerlach, M.J., Koh, E.Y., Zhang, H., Choe, K., Kirschmeier, P., Bishop, W.R., Daley, G.Q. Blood (2001) [Pubmed]
  27. Mechanisms of granulocytosis in the absence of CD18. Horwitz, B.H., Mizgerd, J.P., Scott, M.L., Doerschuk, C.M. Blood (2001) [Pubmed]
  28. Disruption of the estrogen receptor beta gene in mice causes myeloproliferative disease resembling chronic myeloid leukemia with lymphoid blast crisis. Shim, G.J., Wang, L., Andersson, S., Nagy, N., Kis, L.L., Zhang, Q., Mäkelä, S., Warner, M., Gustafsson, J.A. Proc. Natl. Acad. Sci. U.S.A. (2003) [Pubmed]
  29. Lupus susceptibility loci in New Zealand mice. Kono, D.H., Burlingame, R.W., Owens, D.G., Kuramochi, A., Balderas, R.S., Balomenos, D., Theofilopoulos, A.N. Proc. Natl. Acad. Sci. U.S.A. (1994) [Pubmed]
  30. Dysregulated myelopoiesis in mice lacking Jak3. Grossman, W.J., Verbsky, J.W., Yang, L., Berg, L.J., Fields, L.E., Chaplin, D.D., Ratner, L. Blood (1999) [Pubmed]
  31. Transgenic expression of Fas in T cells blocks lymphoproliferation but not autoimmune disease in MRL-lpr mice. Fukuyama, H., Adachi, M., Suematsu, S., Miwa, K., Suda, T., Yoshida, N., Nagata, S. J. Immunol. (1998) [Pubmed]
  32. Complete loss of Fas ligand gene causes massive lymphoproliferation and early death, indicating a residual activity of gld allele. Karray, S., Kress, C., Cuvellier, S., Hue-Beauvais, C., Damotte, D., Babinet, C., Lévi-Strauss, M. J. Immunol. (2004) [Pubmed]
  33. Genetics of susceptibility to leishmaniasis in mice: four novel loci and functional heterogeneity of gene effects. Havelková, H., Badalová, J., Svobodová, M., Vojtíková, J., Kurey, I., Vladimirov, V., Demant, P., Lipoldová, M. Genes. Immun. (2006) [Pubmed]
  34. Susceptibility to Leishmania major infection in mice: multiple loci and heterogeneity of immunopathological phenotypes. Lipoldová, M., Svobodová, M., Krulová, M., Havelková, H., Badalová, J., Nohýnková, E., Holán, V., Hart, A.A., Volf, P., Demant, P. Genes. Immun. (2000) [Pubmed]
  35. Distinct genetic control of parasite elimination, dissemination, and disease after Leishmania major infection. Kurey, I., Kobets, T., Havelková, H., Slapnicková, M., Quan, L., Trtková, K., Grekov, I., Svobodová, M., Stassen, A.P., Hutson, A., Demant, P., Lipoldová, M. Immunogenetics. (2009) [Pubmed]
  36. Different genetic control of cutaneous and visceral disease after Leishmania major infection in mice. Vladimirov, V., Badalová, J., Svobodová, M., Havelková, H., Hart, A.A., Blazková, H., Demant, P., Lipoldová, M. Infect. Immun. (2003) [Pubmed]
  37. Relevance of the mTOR signaling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension. Mejias, M., Garcia-Pras, E., Gallego, J., Mendez, R., Bosch, J., Fernandez, M. J. Hepatol. (2010) [Pubmed]
  38. Evolution of B cell lineage lymphomas in mice with a retrovirus-induced immunodeficiency syndrome, MAIDS. Klinken, S.P., Fredrickson, T.N., Hartley, J.W., Yetter, R.A., Morse, H.C. J. Immunol. (1988) [Pubmed]
  39. Difficult preoperative diagnosis of a patient with sclerosing splenic hemangioma. Edoute, Y., Ben-Haim, S.A., Ben-Arie, Y., Fishman, A., Barzilai, D. Am. J. Gastroenterol. (1989) [Pubmed]
  40. Augmented expression of cytokines in mouse epidermal tumor cells and its possible involvement in the induction of hematopoietic alterations. Bauluz, C., Larcher, F., Ballestin, C., Grande, T., Jorcano, J.L. Mol. Carcinog. (1994) [Pubmed]
  41. Interferon is effective in hairy-cell leukaemia. Worman, C.P., Catovsky, D., Bevan, P.C., Camba, L., Joyner, M., Green, P.J., Williams, H.J., Bottomley, J.M., Gordon-Smith, E.C., Cawley, J.C. Br. J. Haematol. (1985) [Pubmed]
  42. Single dose metrifonate or praziquantel treatment in Kenyan children. I. Effects on Schistosoma haematobium, hookworm, hemoglobin levels, splenomegaly, and hepatomegaly. Stephenson, L.S., Kinoti, S.N., Latham, M.C., Kurz, K.M., Kyobe, J. Am. J. Trop. Med. Hyg. (1989) [Pubmed]
WikiGenes - Universities